Antivirals against enteroviruses: A critical review from a public-health perspective

Antiviral Therapy

Volumn 20, Issue 2, 2015, Pages 121-130

  Benschop, Kimberley S M ^a   Van Der Avoort, Harrie Gam ^a   Duizer, Erwin ^a   Koopmans, Marion P G ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AG 7404; AMANTADINE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BOSENTAN; CAPSID INHIBITOR; DISOXARIL; ENVIROXIME; FLUOXETINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OSELTAMIVIR; PEGINTERFERON; PIRODAVIR; PLECONARIL; POLIOMYELITIS VACCINE; PROTEINASE INHIBITOR; RIBAVIRIN; RUPINTRIVIR; TBZE 029; TRANSFER RNA; UNCLASSIFIED DRUG; V 073; VALSARTAN; VAPENDAVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON COLD; CROSS RESISTANCE; CVB3 INFECTION; DEPRESSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENDEMIC SPECIES; ENTEROVIRUS; ENTEROVIRUS 71; ENTEROVIRUS A; ENTEROVIRUS B; ENTEROVIRUS INFECTION; ERADICATION THERAPY; FECAL ORAL TRANSMISSION; FOOT AND MOUTH DISEASE VIRUS; HAND FOOT AND MOUTH DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; HYGIENE; IMMUNITY; INFECTION CONTROL; INFLUENZA; INFLUENZA A; INFLUENZA VIRUS; LONG TERM CARE; MIXED INFECTION; MYOCARDITIS; NEWBORN SEPSIS; NON POLIO ENTEROVIRUS; NON POLIO ENTEROVIRUS INFECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PICORNAVIRIDAE; PICORNAVIRUS INFECTION; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHINOVIRUS; SYSTEMATIC REVIEW; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; CHILD; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ENTEROVIRUS INFECTIONS; EPIDEMIOLOGICAL MONITORING; GENETICS; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; INFLUENZA, HUMAN; PATHOGENICITY; TRANSMISSION; VIROLOGY;

AMANTADINE; ANTIVIRAL AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG RESISTANCE, VIRAL; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; EPIDEMIOLOGICAL MONITORING; HEPATITIS C; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA, HUMAN; PUBLIC HEALTH; RIBAVIRIN;

EID: 84937560899     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2939     Document Type: Article

References (100)

1. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev 2008; 28:823-884.
2. Rotbart HA. Antiviral therapy for enteroviral infections. Pediatr Infect Dis J 1999; 18:632-633.
3. Chen TC, Shih SR. Drug discovery in enteroviral infections. Infect Disord Drug Targets 2011; 11:337-345.
4. Norder H, De Palma AM, Selisko B, et al. Picornavirus nonstructural proteins as targets for new anti-virals with broad activity. Antiviral Res 2011; 89:204-218.
5. McKinlay MA, Pevear DC, Rossmann MG. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol 1992; 46:635-654.
6. Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res 2008; 79:179-187.
7. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097-1105.
8. Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol 2008; 49:103-112.
9. Tan X, Huang X, Zhu S, et al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS ONE 2011; 6:e25662.
10. Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled Phase 2 clinical trial. Lancet 2013; 381:1037-1045.
11. Kuo RL, Shih SR. Strategies to develop antivirals against enterovirus 71. Virol J 2013; 10:28.
12. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008; 14 Suppl 6:2-8.
13. Nunnery J, Angulo FJ, Tollefson L. Public health and policy. Prev Vet Med 2006; 73:191-195.
14. Teale CJ. Antimicrobial resistance and the food chain. J Appl Microbiol 2002; 92 Suppl:85S-89S.
15. Prasse C, Schlusener MP, Schulz R, Ternes TA. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? Environ Sci Technol 2010; 44:1728-1735.
16. Lee JH, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998; 29:29-35.
17. Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord 2011; 26:1072-1082.
18. Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011; 62:14-25.
19. Zhang G, Zhou F, Gu B, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol 2012; 157:669-679.
20. Li ZH, Li CM, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis 2008; 197:854-857.
21. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375-1379.
22. Park K, Song J, Baek K, et al. Genetic diversity of a Korean echovirus 5 isolate and response of the strain to five antiviral drugs. Virol J 2011; 8:79.
23. Park K, Yeo S, Baek K, et al. Molecular characterization and antiviral activity test of common drugs against echovirus 18 isolated in Korea. Virol J 2011; 8:516.
24. Sadeghipour S, Bek EJ, McMinn PC. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J Virol 2013; 87:1759-1769.
25. Diana GD, Pevear DC, Otto MJ, et al. Inhibitors of viral uncoating. Pharmacol Ther 1989; 42:289-305.
26. Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev 2011; 31:42-92.
27. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 2005; 49:4492-4499.
28. Abzug MJ, Cloud G, Bradley J, et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J 2003; 22:335-341.
29. Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother 2006; 50:2409-2414.
30. Rotbart HA, Webster AD. Treatment of potentially lifethreatening enterovirus infections with pleconaril. Clin Infect Dis 2001; 32:228-235.
31. Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis 2002; 2:264.
32. Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS, Jr. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos 2006; 34:783-785.
33. Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother 2009; 53:4501-4503.
34. Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, Chumakov KM. Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice. Clin Vaccine Immunol 2011; 18:1387-1390.
35. Hayden FG, Hipskind GJ, Woerner DH, et al. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995; 39:290-294.
36. al-Nakib W, Higgins PG, Barrow GI, et al. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother 1989; 33:522-525.
37. Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003; 47:3907-3916.
38. Patick AK, Brothers MA, Maldonado F, et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2005; 49:2267-2275.
39. Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother 1983; 23:671-675.
40. Zhang X, Song Z, Qin B, et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 2013; 97:264-269.
41. Kuo CJ, Shie JJ, Fang JM, et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem 2008; 16:7388-7398.
42. van der Schaar HM, van der Linden L, Lanke KH, et al. Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication. Cell Res 2012; 22:1576-1592.
43. Phillpotts RJ, Jones RW, DeLong DC, Reed SE, Wallace J, Tyrrell DA. The activity of enviroxime against rhinovirus infection in man. Lancet 1981; 1:1342-1344.
44. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009; 27:2649-2652.
45. Branswell H. Hidden and dangerous. Polio could soon be wiped out - but only if scientists can track down the last carriers. Sci Am 2013; 309:14-15.
46. Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013; 87:4907-4922.
47. Combelas N, Holmblat B, Joffret ML, Colbere-Garapin F, Delpeyroux F. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses 2011; 3:1460-1484.
48. Wei H, Huang D, Fortman J, Wang R, Shao L, Chen ZW. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol 2009; 83:1115-1125.
49. Grosenbach DW, Jordan R, King DS, et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008; 26:933-946.
50. Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Antivir Ther 2011; 16:999-1004.
51. Liu HM, Roberts JA, Moore D, et al. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob Agents Chemother 2012; 56:5568-5574.
52. Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res 2011; 90:213-217.
53. Rhoden E, Liu HM, Wang-Chern SW, Oberste MS. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res 2013; 98:186-191.
54. Lukashev AN. Role of recombination in evolution of enteroviruses. Rev Med Virol 2005; 15:157-167.
55. Simmonds P. Recombination and selection in the evolution of picornaviruses and other Mammalian positive-stranded RNA viruses. J Virol 2006; 80:11124-11140.
56. Bessaud M, Delpeyroux F. Development of a simple and rapid protocol for the production of customized intertypic recombinant polioviruses. J Virol Methods 2012; 186:104-108.
57. Mosser AG, Sgro JY, Rueckert RR. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol 1994; 68:8193-8201.
58. Tee KK, Takebe Y, Kamarulzaman A. Emerging and re-emerging viruses in Malaysia, 1997-2007. Int J Infect Dis 2009; 13:307-318.
59. Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007; 356:1226-1234.
60. Hovi T, Shulman LM, van der Avoort H, Deshpande J, Roivainen M, de Gourville EM. Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol Infect 2012; 140:1-13.
61. Rajtar B, Majek M, Polanski L, Polz-Dacewicz M. Enteroviruses in water environment - a potential threat to public health. Ann Agric Environ Med 2008; 15:199-203.
62. Tierney JT, Sullivan R, Larkin EP. Persistence of poliovirus 1 in soil and on vegetables grown in soil previously flooded with inoculated sewage sludge or effluent. Appl Environ Microbiol 1977; 33:109-113.
63. Mesquita JR, Vaz L, Cerqueira S, et al. Norovirus, hepatitis A virus and enterovirus presence in shellfish from high quality harvesting areas in Portugal. Food Microbiol 2011; 28:936-941.
64. Chapman NM, Coppieters K, von Herrath M, Tracy S. The microbiology of human hygiene and its impact on type 1 diabetes. Islets 2012; 4:253-261.
65. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L, Hepatitis A. Epidemiology and prevention in developing countries. World J Hepatol 2012; 4:68-73.
66. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 1979; 110:672-692.
67. Horstmann DM. The poliomyelitis story: a scientific hegira. Yale J Biol Med 1985; 58:79-90.
68. Jutavijittum P, Jiviriyawat Y, Jiviriyawat W, Yousukh A, Hayashi S, Toriyama K. Present epidemiological pattern of antibody to hepatitis a virus among Chiang Mai children, Northern Thailand. Southeast Asian J Trop Med Public Health 2002; 33:268-271.
69. Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 2000; 18 Suppl 1:S61-S64.
70. Wernli D, Haustein T, Conly J, Carmeli Y, Kickbusch I, Harbarth S. A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med 2011; 8:e1001022.
71. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14:17-27.
72. Monto AS. Antivirals and influenza: frequency of resistance. Pediatr Infect Dis J 2008; 27:S110-S112.
73. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
74. He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 2008; 77:72-76.
75. Meijer A, Jonges M, Abbink F, et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res 2011; 92:81-89.
76. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-560.
77. Jonges M, van der Lubben IM, Dijkstra F, Verhoef L, Koopmans M, Meijer A. Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008. Antiviral Res 2009; 83:290-297.
78. Fick J, Lindberg RH, Tysklind M, et al. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS ONE 2007; 2:e986.
79. Pariente N, Sierra S, Airaksinen A. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res 2005; 107:183-193.
80. De Clercq E. The discovery of antiviral agents: ten different compounds, ten different stories. Med Res Rev 2008; 28:929-953.
81. Wyde PR. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 1998; 39:63-79.
82. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20-26.
83. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012; 78:1096-1099.
84. Chen YJ, Zeng SJ, Hsu JT, et al. Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol Sin 2008; 29:1327-1333.
85. Pérez L, Carrasco L. Entry of poliovirus into cells does not require a low-pH step. J Virol 1993; 67:4543-4548.
86. Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010; 463:689-692.
87. De Clercq E. Antivirals: past, present and future. Biochem Pharmacol 2013; 85:727-744.
88. De Palma AM, Heggermont W, Lanke K, et al. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 2008; 82:4720-4730.
89. Ulferts R, van der Linden L, Thibaut HJ, et al. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother 2013; 57:1952-1956.
90. Funke C, Farr M, Werner B, et al. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. J Gen Virol 2010; 91:1959-1970.
91. Buimovici-Klein E, Lange M, Ong KR, Grieco MH, Cooper LZ. Virus isolation and immune studies in a cohort of homosexual men. J Med Virol 1988; 25:371-385.
92. Tormey VJ, Buscombe JR, Johnson MA, Thomson AP, Webster AD. SPECT scans for monitoring response to pleconaril therapy in chronic enteroviral meningoencephalitis. J Infect 2003; 46:138-140.
93. Cunningham AL, Grohman GS, Harkness J, et al. Gastrointestinal viral infections in homosexual men who were symptomatic and seropositive for human immunodeficiency virus. J Infect Dis 1988; 158:386-391.
94. Mansuy JM, Mengelle C, Da Silva I, Grog I, Saune K, Izopet J. Performance of a rapid molecular multiplex assay for the detection of influenza and picornaviruses. Scand J Infect Dis 2012; 44:963-968.
95. Niesters HG, Rossen JW, van der Avoort H, et al. Laboratory-based surveillance in the molecular era: the TYPENED model, a joint data-sharing platform for clinical and public health laboratories. Euro Surveill 2013; 18:20387.
96. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999; 43:2109-2115.
97. Wang Y, Feng Z, Yang Y, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology 2011; 22:781-792.
98. van der Sanden SM, Koopmans MP, van Der Avoort HG. Detection of human enteroviruses and parechoviruses as part of the national enterovirus surveillance in the Netherlands, 1996-2011. Eur J Clin Microbiol Infect Dis 2013; 32:1525-1531.
99. McKinlay MA, Frank JA, Jr., Benziger DP, Steinberg BA. Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. J Infect Dis 1986; 154:676-681.
100. Lim T, Yuan J, Zhang HM, et al. Antisense DNA and RNA agents against picornaviruses. Front Biosci 2008; 13:4707-4725.